Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever

Rift Valley Fever virus (RVFV) causes recurrent outbreaks of acute life-threatening human and livestock illness in Africa and the Arabian Peninsula. No licensed vaccines are currently available for humans and those widely used in livestock have major safety concerns. A 'One Health' vaccine...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2016-02, Vol.6 (1), p.20617-20617, Article 20617
Main Authors: Warimwe, George M, Gesharisha, Joseph, Carr, B Veronica, Otieno, Simeon, Otingah, Kennedy, Wright, Danny, Charleston, Bryan, Okoth, Edward, Elena, Lopez-Gil, Lorenzo, Gema, Ayman, El-Behiry, Alharbi, Naif K, Al-dubaib, Musaad A, Brun, Alejandro, Gilbert, Sarah C, Nene, Vishvanath, Hill, Adrian V S
Format: Article
Language:English
Subjects:
Adenovirus Vaccines - administration & dosage
Adenovirus Vaccines - pharmacology
Adenoviruses
Animals
Antibodies, Neutralizing - metabolism
Camelus
Cattle
Clinical trials
Coccidioidomycosis
Glycoproteins
Goats
Humans
Livestock
Outbreaks
Pan troglodytes - immunology
Pan troglodytes - virology
Replication
Rift Valley fever
Rift Valley Fever - immunology
Rift Valley Fever - prevention & control
Rift Valley fever virus - genetics
Rift Valley fever virus - immunology
Rift Valley fever virus - metabolism
Saudi Arabia - epidemiology
Sheep
United Kingdom - epidemiology
Vaccination
Vaccine development
Vaccines
Vaccines, Synthetic - administration & dosage
Viral Envelope Proteins - genetics
Viral Envelope Proteins - immunology
Viral Vaccines - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rift Valley Fever virus (RVFV) causes recurrent outbreaks of acute life-threatening human and livestock illness in Africa and the Arabian Peninsula. No licensed vaccines are currently available for humans and those widely used in livestock have major safety concerns. A 'One Health' vaccine development approach, in which the same vaccine is co-developed for multiple susceptible species, is an attractive strategy for RVFV. Here, we utilized a replication-deficient chimpanzee adenovirus vaccine platform with an established human and livestock safety profile, ChAdOx1, to develop a vaccine for use against RVFV in both livestock and humans. We show that single-dose immunization with ChAdOx1-GnGc vaccine, encoding RVFV envelope glycoproteins, elicits high-titre RVFV-neutralizing antibody and provides solid protection against RVFV challenge in the most susceptible natural target species of the virus-sheep, goats and cattle. In addition we demonstrate induction of RVFV-neutralizing antibody by ChAdOx1-GnGc vaccination in dromedary camels, further illustrating the potency of replication-deficient chimpanzee adenovirus vaccine platforms. Thus, ChAdOx1-GnGc warrants evaluation in human clinical trials and could potentially address the unmet human and livestock vaccine needs.
ISSN:2045-2322
2045-2322
DOI:10.1038/srep20617